Answers are grounded in this paper and cite their sources.
A bstract Background: Various agents have been used to accelerate the rate of cervical dilatation with subsequent reduction in the duration of labor, thus preventing prolonged labor. Objectives: To determine the efficacy of hyoscine butyl bromide in reducing the duration of labor in nulliparous women at term. Materials and Methods: This was a double blind randomized controlled study conducted among nulliparous women presenting in the active phase of labor at Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Nigeria over a 6-month period. There were 174 participants, among whom 86 received the test drug (intervention group) and 88 received placebo (control group). A P value ≤ 0.05 was considered significant. Results: The mean duration of labor in the 1st stage was 222.45 ± 119.8 min for participants who received hyoscine and 282.50 ± 130.5 min for participants who received placebo only, and the difference was statistically significant ( P = 0.02). The rate of cervical dilatation was significantly faster in women who received hyoscine (2.3 ± 2.8 cm/h) than in those who received placebo (1.7 ± 2.7 cm per hour; P = 0.01). The mean duration of labor in the second stage for the intervention and control groups was 36.67 ± 17.2 and 36.12 ± 17.1, respectively ( P = 0.02). The maternal and neonatal adverse events including nausea, vomiting, and birth asphyxia were similar in both groups ( P > 0.05). Conclusion: Hyoscine butyl bromide was effective in shortening the first stage of labor by accelerating cervical dilatation and had no associated adverse feto-maternal outcome. The Clinical Trial registration number is PACTR202409867055348.
No takes yet. Share an insight, caveat, or question.
Asogwa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: